Fig. 5

Mean change in IDSIQ total score in responders and non-responders treated with daridorexant 50 mg or placebo. Mean (± SE) change in IDSIQ total score over time in responders and non-responders receiving daridorexant 50 mg or placebo. A patient was defined as a ‘responder’ if decrease from baseline in IDSIQ total score at a given timepoint was ≥ 20–points. IDSIQ, Insomnia Daytime Symptoms and Impacts Questionnaire